化合物T12852 新品

Description

SBFI-26 is a selective and competitive inhibitor of fatty acid binding proteins FABP5 and FABP7, with Kis of 0.9 µM and 0.4 µM for FABP5 and FABP7, respectively. SBFI-26 produces anti-nociceptive and anti-inflammatory effects

Target

Ki: 0.9 μM (FABP5), 0.4 µM (FABP7)[1][2]

In Vitro

SBFI-26 binds to the canonical ligand-binding pocket of FABP5[1]. SBFI-26 significantly inhibits cellular AEA accumulation[2].

In Vivo

SBFI-26 (20 mg/kg, i.p.) significantly reduces carrageenan-induced thermal hyperalgesia and paw edema[2]. SBFI-26 produces antinociceptive and anti-inflammatory effects in mice[2]. Animal Model: Mice[2] Dosage: 20 mg/kg Administration: Intraperitoneal injection Result: Significantly reduced carrageenan-induced thermal hyperalgesia and paw edema.